投資概要
公司半年報業績增長顯著，營業收入同比增長 35.36%，歸母淨利潤增長 44.81%。全年業績增長確定性強，我們調高 2018/19 年每股淨收益預測 2.11 元/2.97 元。由於近期市場波動，調低目標市盈率至 20 倍，6 個月目標價 42.2 元，建議短期謹慎操作，逢低收集。(現價截至 10 月 12 日)
Graduated from Hong Kong Polytechnic University, Master of Finance (Investment Management). Possess bachelor degree majoring in Financial Management from Southwestern University of Finance and Economics. Focus on industry prospect and corporate fundamentals to explore investment value and cover pharmaceutical and consumer industry.
